172 is the total number of securities Casdin Capital, LLC has owned. The longest Casdin Capital, LLC has owned a single stock is 32 quarters.
Period | Weighting | Quarter | |||||||
---|---|---|---|---|---|---|---|---|---|
Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
BPMC | BLUEPRINT MEDICINES CORP | 32 | 32 | 2.06% | 5.90% | 9.62% | Q4 2015 | Q3 2023 | 32 |
ALNY | ALNYLAM PHARMACEUTICAL... | 32 | 32 | 1.66% | 4.85% | 9.93% | Q4 2015 | Q3 2023 | 32 |
AGIO | AGIOS PHARMACEUTICALS INC | 27 | 27 | 1.47% | 4.47% | 12.08% | Q4 2015 | Q2 2022 | 27 |
GBT | GLOBAL BLOOD THERAPEUT... | 27 | 27 | 0.98% | 2.40% | 7.10% | Q4 2015 | Q2 2022 | 27 |
FATE | FATE THERAPEUTICS INC | 26 | 26 | 0.48% | 4.32% | 8.35% | Q2 2017 | Q3 2023 | 26 |
BLFS | BIOLIFE SOLUTIONS INC | 22 | 22 | 1.60% | 7.40% | 14.91% | Q2 2018 | Q3 2023 | 22 |
CDXS | CODEXIS INC | 21 | 1 | 0.06% | 3.72% | 8.10% | Q1 2017 | Q3 2023 | 22 |
SRPT | SAREPTA THERAPEUTICS INC | 21 | 21 | 0.78% | 5.71% | 13.56% | Q3 2018 | Q3 2023 | 21 |
BLUE | BLUEBIRD BIO INC | 21 | 21 | 1.17% | 4.57% | 7.83% | Q4 2015 | Q4 2020 | 21 |
ILMN | ILLUMINA INC | 14 | 1 | 0.38% | 2.64% | 6.03% | Q4 2015 | Q3 2023 | 21 |
NVTA | INVITAE CORP | 19 | 1 | 0.12% | 6.84% | 17.54% | Q4 2015 | Q1 2023 | 20 |
MYOK | MYOKARDIA INC | 20 | 20 | 1.91% | 4.96% | 7.34% | Q4 2015 | Q3 2020 | 20 |
DNLI | DENALI THERAPEUTICS INC | 20 | 20 | 0.26% | 2.19% | 3.73% | Q4 2018 | Q3 2023 | 20 |
SAGE | SAGE THERAPEUTICS INC | 18 | 1 | 0.37% | 6.33% | 10.94% | Q4 2015 | Q2 2023 | 19 |
VYGR | VOYAGER THERAPEUTICS INC | 19 | 19 | 0.56% | 2.92% | 4.74% | Q4 2015 | Q2 2020 | 19 |
SGMO | SANGAMO THERAPEUTICS INC | 18 | 1 | 0.17% | 2.16% | 5.93% | Q1 2017 | Q2 2022 | 19 |
MGTA | MAGENTA THERAPEUTICS INC | 18 | 18 | 0.03% | 1.96% | 4.78% | Q2 2018 | Q3 2022 | 18 |
GNMK | GENMARK DIAGNOSTICS INC | 16 | 1 | 1.47% | 3.09% | 5.97% | Q4 2015 | Q1 2020 | 17 |
TWST | TWIST BIOSCIENCE CORP | 17 | 17 | 0.58% | 2.03% | 4.19% | Q2 2019 | Q2 2023 | 17 |
ONCE | SPARK THERAPEUTICS INC | 16 | 16 | 3.76% | 6.03% | 11.76% | Q4 2015 | Q3 2019 | 16 |
CDNA | CAREDX INC | 16 | 16 | 0.34% | 1.78% | 3.00% | Q2 2018 | Q1 2022 | 16 |
RVMD | REVOLUTION MEDICINES INC | 15 | 15 | 1.68% | 3.04% | 5.54% | Q1 2020 | Q3 2023 | 15 |
BGNE | BEIGENE LTD | 8 | 1 | 0.43% | 1.38% | 2.07% | Q1 2016 | Q1 2022 | 15 |
EXAS | EXACT SCIENCES CORP | 12 | 1 | 0.46% | 4.00% | 9.26% | Q1 2016 | Q3 2023 | 14 |
EDIT | EDITAS MEDICINE INC | 13 | 1 | 0.78% | 1.31% | 3.39% | Q1 2016 | Q3 2019 | 14 |
LOXO | LOXO ONCOLOGY INC | 13 | 13 | 6.17% | 8.10% | 10.68% | Q4 2015 | Q4 2018 | 13 |
RLAY | RELAY THERAPEUTICS INC | 13 | 13 | 2.88% | 5.14% | 7.73% | Q3 2020 | Q3 2023 | 13 |
EVH | EVOLENT HEALTH INC | 12 | 12 | 0.76% | 3.91% | 7.68% | Q2 2016 | Q1 2019 | 12 |
BOLD | AUDENTES THERAPEUTICS INC | 12 | 12 | 2.38% | 3.13% | 4.73% | Q1 2017 | Q4 2019 | 12 |
CTMX | CYTOMX THERAPEUTICS INC | 12 | 12 | 0.47% | 1.89% | 5.92% | Q4 2015 | Q3 2018 | 12 |
CNST | CONSTELLATION PHARMCET... | 12 | 12 | 0.89% | 1.86% | 5.25% | Q3 2018 | Q2 2021 | 12 |
BEAM | BEAM THERAPEUTICS INC | 12 | 12 | 1.11% | 1.63% | 2.68% | Q4 2020 | Q3 2023 | 12 |
ADPT | ADAPTIVE BIOTECHNOLOGI... | 12 | 12 | 0.62% | 1.44% | 2.34% | Q2 2019 | Q1 2022 | 12 |
ALEC | ALECTOR INC | 12 | 12 | 0.68% | 1.18% | 2.76% | Q1 2019 | Q4 2021 | 12 |
KRON | KRONOS BIO INC | 12 | 12 | 0.02% | 0.19% | 0.52% | Q4 2020 | Q3 2023 | 12 |
FMI | FOUNDATION MEDICINE INC | 11 | 11 | 2.14% | 7.52% | 13.10% | Q4 2015 | Q2 2018 | 11 |
CRSP | CRISPR THERAPEUTICS AG | 8 | 3 | 0.57% | 1.09% | 1.81% | Q1 2018 | Q4 2021 | 11 |
FDMT | 4D MOLECULAR THERAPEUT... | 7 | 4 | 0.33% | 0.95% | 1.69% | Q4 2020 | Q3 2023 | 11 |
ZLAB | ZAI LAB LTD | 9 | 2 | 0.27% | 0.64% | 1.04% | Q1 2018 | Q1 2022 | 11 |
STOK | STOKE THERAPEUTICS INC | 11 | 11 | 0.08% | 0.19% | 0.34% | Q2 2019 | Q4 2021 | 11 |
VERV | VERVE THERAPEUTICS INC | 10 | 10 | 2.52% | 4.01% | 7.17% | Q2 2021 | Q3 2023 | 10 |
PACB | PACIFIC BIOSCIENCES CA... | 7 | 1 | 0.40% | 3.17% | 5.08% | Q1 2017 | Q3 2023 | 10 |
IPSC | CENTURY THERAPEUTICS INC | 10 | 10 | 0.71% | 1.58% | 2.39% | Q2 2021 | Q3 2023 | 10 |
OMIC | SINGULAR GENOMICS SYST... | 10 | 10 | 0.06% | 0.45% | 1.88% | Q2 2021 | Q3 2023 | 10 |
GLUE | MONTE ROSA THERAPEUTIC... | 10 | 10 | 0.27% | 0.41% | 0.60% | Q2 2021 | Q3 2023 | 10 |
MAXCYTE INC | 9 | 9 | 0.65% | 3.49% | 5.59% | Q3 2021 | Q3 2023 | 9 | |
SOMALOGIC INC | 9 | 9 | 2.40% | 3.38% | 4.74% | Q3 2021 | Q3 2023 | 9 | |
CLVS | CLOVIS ONCOLOGY INC | 7 | 2 | 0.84% | 2.18% | 4.50% | Q2 2016 | Q3 2018 | 9 |
TENAYA THERAPEUTICS INC | 9 | 9 | 0.68% | 1.72% | 3.27% | Q3 2021 | Q3 2023 | 9 | |
ABSCI CORPORATION | 9 | 9 | 0.14% | 1.44% | 2.92% | Q3 2021 | Q3 2023 | 9 | |
DERMTECH INC | 9 | 9 | 0.60% | 1.29% | 2.64% | Q1 2020 | Q1 2022 | 9 | |
ORTX | ORCHARD THERAPEUTICS PLC | 6 | 3 | 0.13% | 0.50% | 1.04% | Q2 2019 | Q3 2021 | 9 |
ORIC | ORIC PHARMACEUTICALS INC | 9 | 9 | 0.14% | 0.34% | 0.60% | Q2 2020 | Q2 2022 | 9 |
TPTX | TURNING POINT THERAPEU... | 9 | 9 | 0.15% | 0.28% | 0.43% | Q2 2019 | Q2 2021 | 9 |
EQRX INC | 8 | 8 | 6.32% | 9.18% | 15.68% | Q4 2021 | Q3 2023 | 8 | |
KITE | KITE PHARMA INC | 8 | 8 | 1.63% | 3.44% | 5.38% | Q4 2015 | Q3 2017 | 8 |
GRTS | GRITSTONE ONCOLOGY INC | 8 | 8 | 0.73% | 1.52% | 1.90% | Q3 2018 | Q2 2020 | 8 |
GBIO | GENERATION BIO CO | 8 | 8 | 0.26% | 1.20% | 2.23% | Q2 2020 | Q1 2022 | 8 |
ALLO | ALLOGENE THERAPEUTICS INC | 8 | 8 | 0.71% | 1.19% | 1.60% | Q1 2020 | Q4 2021 | 8 |
FULC | FULCRUM THERAPEUTICS INC | 8 | 8 | 0.31% | 0.91% | 1.90% | Q3 2019 | Q2 2021 | 8 |
EXSCIENTIA PLC | 8 | 8 | 0.09% | 0.25% | 0.61% | Q4 2021 | Q3 2023 | 8 | |
LIANBIO | 8 | 8 | 0.03% | 0.03% | 0.04% | Q4 2021 | Q3 2023 | 8 | |
EPZM | EPIZYME INC | 7 | 7 | 2.35% | 4.10% | 7.58% | Q4 2015 | Q2 2017 | 7 |
JNCE | JOUNCE THERAPEUTICS INC | 7 | 7 | 0.30% | 1.28% | 2.50% | Q1 2017 | Q3 2018 | 7 |
TANGO THERAPEUTICS INC | 4 | 3 | 0.29% | 1.27% | 1.86% | Q3 2021 | Q3 2023 | 7 | |
SEMA4 HOLDINGS CORP | 7 | 7 | 0.34% | 1.20% | 3.07% | Q3 2021 | Q1 2023 | 7 | |
ABCL | ABCELLERA BIOLOGICS INC | 6 | 1 | 0.24% | 1.14% | 1.78% | Q4 2020 | Q3 2023 | 7 |
SYRS | SYROS PHARMACEUTICALS INC | 7 | 7 | 0.56% | 1.12% | 1.83% | Q2 2016 | Q4 2017 | 7 |
MRTX | MIRATI THERAPEUTICS INC | 7 | 7 | 0.08% | 1.11% | 2.40% | Q1 2022 | Q3 2023 | 7 |
ADVM | ADVERUM BIOTECHNOLOGIE... | 5 | 1 | 0.31% | 1.08% | 2.30% | Q1 2017 | Q1 2021 | 7 |
2SEVENTY BIO INC | 7 | 7 | 0.47% | 1.06% | 1.79% | Q1 2022 | Q3 2023 | 7 | |
FIXX | HOMOLOGY MEDICINES INC | 7 | 7 | 0.20% | 0.97% | 1.54% | Q1 2018 | Q3 2019 | 7 |
BLI | BERKELEY LTS INC | 6 | 6 | 0.10% | 0.32% | 0.68% | Q3 2020 | Q4 2021 | 6 |
SEER | SEER INC | 6 | 6 | 0.12% | 0.30% | 0.55% | Q4 2020 | Q1 2022 | 6 |
SANA | SANA BIOTECHNOLOGY INC | 4 | 2 | 0.03% | 0.14% | 0.39% | Q1 2021 | Q3 2023 | 6 |
NTLA | INTELLIA THERAPEUTICS INC | 5 | 5 | 0.80% | 2.89% | 4.54% | Q3 2022 | Q3 2023 | 5 |
PLRX | PLIANT THERAPEUTICS INC | 5 | 5 | 1.03% | 2.59% | 3.67% | Q3 2022 | Q3 2023 | 5 |
GILD | GILEAD SCIENCES INC | 1 | 1 | 0.52% | 1.04% | 1.96% | Q4 2016 | Q1 2020 | 5 |
BMYRT | BRISTOL-MYERS SQUIBB CO | 5 | 5 | 0.13% | 0.56% | 1.01% | Q4 2019 | Q4 2020 | 5 |
DCPH | DECIPHERA PHARMACEUTIC... | 5 | 5 | 0.15% | 0.56% | 1.46% | Q3 2019 | Q3 2020 | 5 |
MASS | 908 DEVICES INC | 5 | 5 | 0.30% | 0.46% | 0.69% | Q4 2020 | Q4 2021 | 5 |
DBTX | DECIBEL THERAPEUTICS INC | 5 | 5 | 0.04% | 0.21% | 0.39% | Q1 2021 | Q1 2022 | 5 |
TSRO | TESARO INC | 3 | 1 | 1.40% | 1.79% | 2.48% | Q2 2016 | Q3 2017 | 4 |
BNR | BURNING ROCK BIOTECH LTD | 4 | 4 | 0.68% | 1.73% | 2.77% | Q2 2020 | Q1 2021 | 4 |
RNA | AVIDITY BIOSCIENCES INC | 4 | 4 | 0.82% | 1.06% | 1.46% | Q4 2022 | Q3 2023 | 4 |
AMRS | AMYRIS INC | 2 | 1 | 0.59% | 1.04% | 1.35% | Q2 2017 | Q2 2021 | 4 |
OSUR | ORASURE TECHNOLOGIES INC | 3 | 1 | 0.71% | 1.04% | 1.47% | Q4 2015 | Q3 2018 | 4 |
PRIME MEDICINE INC | 4 | 4 | 0.39% | 0.66% | 1.06% | Q4 2022 | Q3 2023 | 4 | |
BDTX | BLACK DIAMOND THERAPEU... | 4 | 4 | 0.28% | 0.54% | 0.77% | Q1 2020 | Q4 2020 | 4 |
SNDX | SYNDAX PHARMACEUTICALS... | 4 | 4 | 0.30% | 0.51% | 0.67% | Q4 2020 | Q3 2021 | 4 |
RXRX | RECURSION PHARMACEUTIC... | 4 | 4 | 0.18% | 0.32% | 0.51% | Q2 2021 | Q1 2022 | 4 |
FHTX | FOGHORN THERAPEUTICS INC | 4 | 4 | 0.06% | 0.09% | 0.13% | Q4 2020 | Q3 2021 | 4 |
STRUCTURE THERAPEUTICS... | 3 | 3 | 1.33% | 3.94% | 6.86% | Q1 2023 | Q3 2023 | 3 | |
XBI | SPDR SERIES TRUST | 2 | 1 | 1.61% | 2.95% | 4.28% | Q1 2016 | Q2 2017 | 3 |
GHDX | GENOMIC HEALTH INC | 2 | 1 | 1.56% | 2.93% | 5.13% | Q4 2015 | Q3 2016 | 3 |
MDRX | ALLSCRIPTS HEALTHCARE ... | 3 | 3 | 2.13% | 2.27% | 2.36% | Q3 2016 | Q1 2017 | 3 |
DXCM | DEXCOM INC | 3 | 3 | 1.18% | 1.84% | 3.12% | Q4 2015 | Q2 2016 | 3 |
BMY | BRISTOL MYERS SQUIBB CO | 3 | 3 | 1.54% | 1.68% | 1.96% | Q4 2015 | Q2 2016 | 3 |
GH | GUARDANT HEALTH INC | 3 | 3 | 0.93% | 1.47% | 2.23% | Q4 2021 | Q2 2022 | 3 |
IBB | ISHARES TR | 1 | 1 | 0.99% | 1.32% | 1.78% | Q3 2016 | Q4 2018 | 3 |
RXDX | IGNYTA INC | 3 | 3 | 0.86% | 1.29% | 2.02% | Q1 2016 | Q3 2016 | 3 |
GINKGO BIOWORKS HOLDIN... | 3 | 3 | 0.76% | 1.28% | 2.08% | Q3 2021 | Q1 2022 | 3 | |
GILD | GILEAD SCIENCES INC | 1 | 1 | 0.47% | 1.08% | 1.57% | Q2 2017 | Q4 2019 | 3 |
NEOG | NEOGEN CORP | 3 | 3 | 0.56% | 0.69% | 0.77% | Q1 2018 | Q3 2018 | 3 |
TSHA | TAYSHA GENE THERAPIES INC | 3 | 3 | 0.50% | 0.65% | 0.82% | Q3 2020 | Q1 2021 | 3 |
OVID | OVID THERAPEUTICS INC | 3 | 3 | 0.38% | 0.58% | 0.86% | Q2 2017 | Q4 2017 | 3 |
ME | 23ANDME HOLDING CO | 3 | 3 | 0.35% | 0.52% | 0.81% | Q2 2021 | Q4 2021 | 3 |
INCY | INCYTE CORP | 3 | 3 | 0.42% | 0.46% | 0.48% | Q4 2022 | Q2 2023 | 3 |
NTGN | NEON THERAPEUTICS INC | 3 | 3 | 0.23% | 0.39% | 0.60% | Q2 2018 | Q4 2018 | 3 |
SCIENCE 37 HOLDINGS INC | 3 | 3 | 0.04% | 0.37% | 0.63% | Q4 2021 | Q2 2022 | 3 | |
DYN | DYNE THERAPEUTICS INC | 3 | 3 | 0.23% | 0.28% | 0.33% | Q3 2020 | Q1 2021 | 3 |
AMRS | AMYRIS INC | 2 | 2 | 1.88% | 1.97% | 2.06% | Q4 2016 | Q1 2017 | 2 |
BIIB | BIOGEN INC | 2 | 2 | 1.49% | 1.96% | 2.44% | Q4 2015 | Q1 2016 | 2 |
ILMN | ILLUMINA INC | 1 | 1 | 0.38% | 1.89% | 3.39% | Q4 2015 | Q3 2023 | 2 |
AVXS | AVEXIS INC | 2 | 2 | 1.70% | 1.84% | 1.97% | Q1 2016 | Q2 2016 | 2 |
GENEDX HOLDINGS CORP | 2 | 2 | 1.25% | 1.43% | 1.61% | Q2 2023 | Q3 2023 | 2 | |
RXDX | PROMETHEUS BIOSCIENCES... | 2 | 2 | 1.28% | 1.30% | 1.33% | Q4 2022 | Q1 2023 | 2 |
MDGN | MEDGENICS INC | 2 | 2 | 0.47% | 1.08% | 1.69% | Q2 2016 | Q3 2016 | 2 |
IOVA | IOVANCE BIOTHERAPEUTIC... | 2 | 2 | 0.43% | 0.59% | 0.76% | Q3 2020 | Q4 2020 | 2 |
CELG | CELGENE CORP | 1 | 1 | 0.54% | 0.59% | 0.63% | Q1 2018 | Q3 2018 | 2 |
DICE THERAPEUTICS INC | 2 | 2 | 0.40% | 0.57% | 0.73% | Q4 2022 | Q1 2023 | 2 | |
ARVN | ARVINAS INC | 2 | 2 | 0.53% | 0.56% | 0.58% | Q3 2022 | Q4 2022 | 2 |
MRNA | MODERNA INC | 2 | 2 | 0.25% | 0.54% | 0.84% | Q3 2022 | Q4 2022 | 2 |
OXFD | OXFORD IMMUNOTEC GLOBA... | 2 | 2 | 0.23% | 0.50% | 0.76% | Q4 2015 | Q1 2016 | 2 |
OPRX | OPTIMIZERX CORP | 2 | 2 | 0.34% | 0.47% | 0.60% | Q4 2022 | Q1 2023 | 2 |
MDSO | MEDIDATA SOLUTIONS INC | 2 | 2 | 0.44% | 0.44% | 0.44% | Q4 2015 | Q1 2016 | 2 |
MRTX | MIRATI THERAPEUTICS INC | 2 | 2 | 0.35% | 0.40% | 0.46% | Q3 2022 | Q4 2022 | 2 |
CLDX | CELLDEX THERAPEUTICS I... | 2 | 2 | 0.30% | 0.34% | 0.38% | Q2 2022 | Q3 2022 | 2 |
AGIO | AGIOS PHARMACEUTICALS INC | 1 | 1 | 0.29% | 0.32% | 0.35% | Q4 2015 | Q4 2017 | 2 |
FLDM | STANDARD BIOTOOLS INC | 2 | 2 | 0.20% | 0.29% | 0.38% | Q2 2023 | Q3 2023 | 2 |
LEGN | LEGEND BIOTECH CORP | 2 | 2 | 0.19% | 0.27% | 0.34% | Q2 2020 | Q3 2020 | 2 |
CRIS | CURIS INC | 2 | 2 | 0.06% | 0.22% | 0.38% | Q1 2017 | Q2 2017 | 2 |
CLOV | CLOVER HEALTH INVESTME... | 2 | 2 | 0.16% | 0.20% | 0.25% | Q1 2021 | Q2 2021 | 2 |
TKNO | ALPHA TEKNOVA INC | 2 | 2 | 0.18% | 0.18% | 0.19% | Q2 2021 | Q3 2021 | 2 |
NAUT | NAUTILUS BIOTECHNOLOGY... | 2 | 2 | 0.03% | 0.08% | 0.13% | Q2 2021 | Q3 2021 | 2 |
CDAK | CODIAK BIOSCIENCES INC | 2 | 2 | 0.03% | 0.05% | 0.07% | Q4 2020 | Q1 2021 | 2 |
CTLT | CATALENT INC | 1 | 1 | 2.73% | 2.73% | 2.73% | Q2 2023 | Q2 2023 | 1 |
CERN | CERNER CORP | 1 | 1 | 2.54% | 2.54% | 2.54% | Q4 2016 | Q4 2016 | 1 |
SAGE | SAGE THERAPEUTICS INC | 1 | 1 | 1.95% | 1.95% | 1.95% | Q2 2016 | Q2 2016 | 1 |
GNMX | AEVI GENOMIC MEDICINE INC | 1 | 1 | 1.60% | 1.60% | 1.60% | Q4 2016 | Q4 2016 | 1 |
DXCM | DEXCOM INC | 1 | 1 | 1.18% | 1.18% | 1.18% | Q2 2016 | Q2 2016 | 1 |
BLUE | BLUEBIRD BIO INC | 1 | 1 | 1.13% | 1.13% | 1.13% | Q4 2015 | Q4 2015 | 1 |
IONS | IONIS PHARMACEUTICALS INC | 1 | 1 | 0.98% | 0.98% | 0.98% | Q3 2016 | Q3 2016 | 1 |
MYGN | MYRIAD GENETICS INC | 1 | 1 | 0.96% | 0.96% | 0.96% | Q2 2017 | Q2 2017 | 1 |
XLRN | ACCELERON PHARMA INC | 1 | 1 | 0.95% | 0.95% | 0.95% | Q4 2016 | Q4 2016 | 1 |
KRTX | KARUNA THERAPEUTICS INC | 1 | 1 | 0.91% | 0.91% | 0.91% | Q2 2022 | Q2 2022 | 1 |
MDRX | ALLSCRIPTS HEALTHCARE ... | 1 | 1 | 0.71% | 0.71% | 0.71% | Q2 2017 | Q2 2017 | 1 |
JUNO | JUNO THERAPEUTICS INC | 1 | 1 | 0.68% | 0.68% | 0.68% | Q4 2015 | Q4 2015 | 1 |
VEEV | VEEVA SYS INC | 1 | 1 | 0.62% | 0.62% | 0.62% | Q4 2022 | Q4 2022 | 1 |
ATRA | ATARA BIOTHERAPEUTICS INC | 1 | 1 | 0.58% | 0.58% | 0.58% | Q4 2015 | Q4 2015 | 1 |
NEO | NEOGENOMICS INC | 1 | 1 | 0.56% | 0.56% | 0.56% | Q2 2021 | Q2 2021 | 1 |
LOXO | LOXO ONCOLOGY INC | 1 | 1 | 0.48% | 0.48% | 0.48% | Q2 2018 | Q2 2018 | 1 |
MRNA | MODERNA INC | 1 | 1 | 0.42% | 0.42% | 0.42% | Q4 2022 | Q4 2022 | 1 |
ALNY | ALNYLAM PHARMACEUTICAL... | 1 | 1 | 0.39% | 0.39% | 0.39% | Q3 2023 | Q3 2023 | 1 |
AMRS | AMYRIS INC | 1 | 1 | 0.37% | 0.37% | 0.37% | Q4 2020 | Q4 2020 | 1 |
PMVP | PMV PHARMACEUTICALS INC | 1 | 1 | 0.36% | 0.36% | 0.36% | Q2 2022 | Q2 2022 | 1 |
QTNT | QUOTIENT LTD | 1 | 1 | 0.34% | 0.34% | 0.34% | Q4 2018 | Q4 2018 | 1 |
TROV | TROVAGENE INC | 1 | 1 | 0.33% | 0.33% | 0.33% | Q4 2015 | Q4 2015 | 1 |
GBT | GLOBAL BLOOD THERAPEUT... | 1 | 1 | 0.32% | 0.32% | 0.32% | Q2 2018 | Q2 2018 | 1 |
DEFINITIVE HEALTHCARE ... | 1 | 1 | 0.31% | 0.31% | 0.31% | Q4 2022 | Q4 2022 | 1 | |
SRPT | SAREPTA THERAPEUTICS INC | 1 | 1 | 0.28% | 0.28% | 0.28% | Q1 2023 | Q1 2023 | 1 |
FMI | FOUNDATION MEDICINE INC | 1 | 1 | 0.28% | 0.28% | 0.28% | Q4 2015 | Q4 2015 | 1 |
ZYME | ZYMEWORKS INC | 1 | 1 | 0.28% | 0.28% | 0.28% | Q2 2020 | Q2 2020 | 1 |
KROS | KEROS THERAPEUTICS INC | 1 | 1 | 0.24% | 0.24% | 0.24% | Q4 2022 | Q4 2022 | 1 |
VRTX | VERTEX PHARMACEUTICALS... | 1 | 1 | 0.23% | 0.23% | 0.23% | Q3 2021 | Q3 2021 | 1 |
CERE | CEREVEL THERAPEUTICS H... | 1 | 1 | 0.15% | 0.15% | 0.15% | Q3 2022 | Q3 2022 | 1 |
WVE | WAVE LIFE SCIENCES LTD | 1 | 1 | 0.11% | 0.11% | 0.11% | Q4 2022 | Q4 2022 | 1 |
BPMC | BLUEPRINT MEDICINES CORP | 1 | 1 | 0.09% | 0.09% | 0.09% | Q2 2018 | Q2 2018 | 1 |
GBT | GLOBAL BLOOD THERAPEUT... | 1 | 1 | 0.06% | 0.06% | 0.06% | Q4 2020 | Q4 2020 | 1 |
CCCC | C4 THERAPEUTICS INC | 1 | 1 | 0.04% | 0.04% | 0.04% | Q4 2020 | Q4 2020 | 1 |
ZY | ZYMERGEN INC | 1 | 1 | 0.03% | 0.03% | 0.03% | Q2 2021 | Q2 2021 | 1 |
SCILEX HOLDING CO | 1 | 1 | 0.01% | 0.01% | 0.01% | Q2 2023 | Q2 2023 | 1 | |
Download |
The securities at the top of the list , including BLUEPRINT MEDICINES CORP, ALNYLAM PHARMACEUTICALS INC, and AGIOS PHARMACEUTICALS INC, are the highest-conviction holdings of Casdin Capital, LLC.
The conviction is calculated by counting the number of quarters a security has been reported by Casdin Capital, LLC. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that Casdin Capital, LLC owns currently or has owned in the past.